^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TAK-007
i
Other names: TAK-007, TAK007, TAK 007, Anti-CD19 CAR NK-cell therapy, iC9/CAR.19/IL15-Transduced CB-NK Cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Takeda, UT MD Anderson Cancer Center
Drug class:
CD19 inhibitor
Related drugs:
17d
A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) (clinicaltrials.gov)
P1, N=20, Not yet recruiting, Takeda
New P1 trial
|
cyclophosphamide • TAK-007
2ms
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov)
P2, N=265, Recruiting, Takeda | Trial completion date: Oct 2029 --> Jun 2030 | Trial primary completion date: Oct 2029 --> Oct 2025
Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL6 rearrangement • BCL2 rearrangement
|
cyclophosphamide • TAK-007
over2years
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov)
P2; N=242; Recruiting; Sponsor: Takeda; Not yet recruiting ➔ Recruiting
Enrollment open • Clinical
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
|
BCL6 rearrangement • BCL2 rearrangement
|
cyclophosphamide • TAK-007
over2years
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov)
P2, N=242, Not yet recruiting, Takeda
Clinical • New P2 trial
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
|
BCL6 rearrangement • BCL2 rearrangement
|
TAK-007
Share via
